US 12,171,746 B2
Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
Alberto Gabizon, Jerusalem (IL); Patricia Ohana, Jerusalem (IL); and Hilary Shmeeda, Givat Zev (IL)
Assigned to Lipomedix Pharmaceuticals Ltd., Jerusalem (IL); and Sharre Zedek Scientific Ltd., Jerusalem (IL)
Appl. No. 17/421,959
Filed by LIPOMEDIX PHARMACEUTICALS LTD., Jerusalem (IL); and SHAARE ZEDEK SCIENTIFIC LTD., Jerusalem (IL)
PCT Filed Jan. 11, 2020, PCT No. PCT/IB2020/050205
§ 371(c)(1), (2) Date Jul. 9, 2021,
PCT Pub. No. WO2020/144657, PCT Pub. Date Jul. 16, 2020.
Claims priority of provisional application 62/791,718, filed on Jan. 11, 2019.
Prior Publication US 2022/0087975 A1, Mar. 24, 2022
Int. Cl. A61K 31/407 (2006.01); A61K 9/127 (2006.01); A61K 9/16 (2006.01); A61K 47/24 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/407 (2013.01) [A61K 9/127 (2013.01); A61K 9/1617 (2013.01); A61K 47/24 (2013.01); A61P 35/00 (2018.01)] 19 Claims
 
1. A composition comprising:
a population of lipid nanoparticles and a pharmaceutically acceptable vehicle,
wherein the population of lipid nanoparticles is comprised of spherical liposomes and rod-shaped lipid nanoparticles, where less than about 5% of the population of lipid nanoparticles is rod-shaped lipid nanoparticles and, wherein the spherical liposomes are comprised of a vesicle-forming lipid, a lipophilic prodrug of mitomycin C, and an optional lipid component.